FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of $0.62 per share for the year, down from their previous forecast of $0.65. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ FY2029 earnings at $1.71 EPS.

Other equities analysts also recently issued research reports about the stock. William Blair reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. Bank of America lowered their price objective on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Citigroup cut their target price on LENZ Therapeutics from $52.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Wall Street Zen cut LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, LENZ Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $45.60.

LENZ Therapeutics Stock Performance

LENZ Therapeutics stock opened at $8.94 on Thursday. LENZ Therapeutics has a 1 year low of $8.56 and a 1 year high of $50.40. The firm has a 50 day moving average price of $13.95 and a 200 day moving average price of $24.30. The company has a market cap of $280.27 million, a price-to-earnings ratio of -3.18 and a beta of 0.52.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The firm had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LENZ. Versant Venture Management LLC acquired a new position in shares of LENZ Therapeutics during the third quarter worth about $123,758,000. Price T Rowe Associates Inc. MD grew its stake in shares of LENZ Therapeutics by 307.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,023,542 shares of the company’s stock valued at $16,378,000 after buying an additional 772,411 shares in the last quarter. First Light Asset Management LLC purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at about $32,282,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of LENZ Therapeutics by 108.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company’s stock valued at $32,907,000 after buying an additional 585,000 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of LENZ Therapeutics by 6,756.1% during the 3rd quarter. Franklin Resources Inc. now owns 587,084 shares of the company’s stock valued at $27,346,000 after buying an additional 578,521 shares during the period. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics News Roundup

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Company highlighted a successful LNZ100 launch and positioned the program as a potential blockbuster opportunity — product momentum and commercial potential support longer‑term upside. LENZ Therapeutics Surpasses Expectations with LNZ100 Launch
• Positive Sentiment: Q4/2025 earnings call emphasized a strong cash position and operational updates that may de‑risk near‑term funding concerns. That balance‑sheet strength is supportive for execution and runway. LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Citigroup cut its price target substantially from $52 to $26 but kept a “Buy” rating — a meaningful reset in valuation expectations that still implies sizable upside versus current levels. Benzinga
• Neutral Sentiment: Bank of America trimmed its price target to $29 (from $35) while maintaining a “Buy” rating — another analyst recalibration that tempers near‑term price targets but signals continued conviction. LENZ Therapeutics Given New $29.00 Price Target at Bank of America
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS forecasts slightly (FY2028 to $0.62 from $0.65; FY2029 to $1.71 from $1.84) — the analyst kept a Buy rating but the cuts signal moderated profitability expectations out a few years. MarketBeat – HC Wainwright EPS Revisions
• Negative Sentiment: Recent reported Q4 results missed consensus: EPS and revenue were below estimates, and consensus for the current year remains negative — short‑term fundamentals and missed guidance/revenue contributed to the sell‑side caution. LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.